Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen M MacDonald

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Health Affairs (Project Hope)|July 13, 2006
Postapproval drug safetyIvo L Abraham, Karen M MacDonald
The Nursing Clinics of North America|February 24, 2006
Measuring the quality of nursing care to Alzheimer's patientsIvo L Abraham, Karen M MacDonald, Deborah M Nadzam
The Nursing Clinics of North America|February 24, 2006
Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: application to mild and moderate dementiaKaren M MacDonald, Stefaan Vancayzeele, Anne Deblander, et al.
Expert Opinion on Pharmacotherapy|September 29, 2022
Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?Rebecca M Thiede, Mohammad Fazel, Karen M MacDonald, et al.
BMC Pregnancy and Childbirth|July 11, 2006
Maternal serum alpha-fetoprotein levels in fetal hydrocephalus: a retrospective population based studyTerrence P Szajkowski, Bernard N Chodirker, Karen M MacDonald, et al.
Expert Review of Clinical Immunology|February 15, 2019
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018Karen M MacDonald, Abhishek Kavati, Benjamin Ortiz, et al.
Journal of Managed Care & Specialty Pharmacy|January 31, 2022
Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United StatesIvo Abraham, Amit Goyal, Baris Deniz, et al.
Prenatal Diagnosis|July 30, 2005
Screening for open neural tube defects from 21 to 25 weeks' gestation: the Manitoba experienceNatalie K Björklund, Karen M MacDonald, Jane A Evans, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Health Affairs (Project Hope)|July 13, 2006
Postapproval drug safetyIvo L Abraham, Karen M MacDonald
The Nursing Clinics of North America|February 24, 2006
Measuring the quality of nursing care to Alzheimer's patientsIvo L Abraham, Karen M MacDonald, Deborah M Nadzam
The Nursing Clinics of North America|February 24, 2006
Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: application to mild and moderate dementiaKaren M MacDonald, Stefaan Vancayzeele, Anne Deblander, et al.
Expert Opinion on Pharmacotherapy|September 29, 2022
Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?Rebecca M Thiede, Mohammad Fazel, Karen M MacDonald, et al.
BMC Pregnancy and Childbirth|July 11, 2006
Maternal serum alpha-fetoprotein levels in fetal hydrocephalus: a retrospective population based studyTerrence P Szajkowski, Bernard N Chodirker, Karen M MacDonald, et al.
Expert Review of Clinical Immunology|February 15, 2019
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018Karen M MacDonald, Abhishek Kavati, Benjamin Ortiz, et al.
Journal of Managed Care & Specialty Pharmacy|January 31, 2022
Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United StatesIvo Abraham, Amit Goyal, Baris Deniz, et al.
Prenatal Diagnosis|July 30, 2005
Screening for open neural tube defects from 21 to 25 weeks' gestation: the Manitoba experienceNatalie K Björklund, Karen M MacDonald, Jane A Evans, et al.
Pageof 1